Inclusion Criteria:

- polymerase chain reaction (PCR) confirmed coronavirus infection (COVID-19) in
hospitalized patients with severe risk factors in age from 18 years to 59 years, of
both sexes, irrespective of national or ethnic origin

- the duration of the COVID-19 disease is no more than 10 days

- informed concent to participate in clinical trials

- informed concent to to use reliable contraceptive methods while participating in a
clinical trial

Exclusion Criteria:

- age less than 18 years old and over 59 years old

- pregnancy or breastfeeding

- hypersensitivity, allergy, intolerance to iodine, iodine-containing medicines

- hypersensitivity to Remdesivir or its components

- impaired consciousness, causing the impossibility of oral administration

- conditions or circumstances that, in the opinion of the investigator, may affect the
patient's safety or the quality of the results obtained

- participation in another clinical trial, including in the period up to 2 months
before this study

- signs of multiple organ failure

- alanine aminotransferase (ALT), aspartate aminotransferase (AST) is 5 or more times
higher than normal

- thrombocytopenia below 100 * 10^9/ l

- decrease in glomerular filtration rate (GFR) less than 30 ml / min by 1.73 m2

- chronic heart failure with reduced ejection fraction

- liver failure

- coagulopathy

- mechanical ventilation for 48 hours or more

- extracorporeal membrane oxygenation (ECMO)

- disseminated intravascular coagulation